Recent advances in research and development of new small molecule immunosuppressants for inflammatory bowel disease / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1289-1301, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-779999
ABSTRACT
Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disorder including mainly ulcerative colitis (UC) and Crohn's disease (CD). In China, IBD has become a common disease of the digestive system with an dramatic increase in incidence in recent years. The pathogenesis of IBD is not yet clear, and no drugs can completely cure IBD. Compared with monoclonal antibody drugs, small molecule drugs have the advantages of low cost, easy development as oral agents, and absence of immunogenicity. This review summarizes the recent research and development of small molecule immunosuppressants for IBD.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Acta Pharmaceutica Sinica
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS